Stock 002773 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

News Chengdu Kanghong Pharmaceutical Group Co., Ltd

Equities

002773

CNE1000020C4

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 31/05/2024 am IST 		5-day change 1st Jan Change
22.35 CNY +0.13% Intraday chart for Chengdu Kanghong Pharmaceutical Group Co., Ltd -1.15% +21.20%
22/05 Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 May 2024 CI
29/04 Kanghong Pharmaceutical's Unit Gets US FDA's Green Light to Test Macular Degeneration Drug MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 May 2024
CI
Kanghong Pharmaceutical's Unit Gets US FDA's Green Light to Test Macular Degeneration Drug
MT
Kanghong Pharmaceutical's Unit Gets Nod to Trial Macular Degeneration Drug
MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023
CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Kanghong Pharmaceutical's Mosapride Citrate Tablets Wins Centralized Procurement Bid
MT
Kanghong Pharmaceutical's Beijing Unit Gets China's Approval for Clinical Trials for Anti-Tumor Injection
MT
Kanghong Pharmaceutical's Unit Gets Nod to Trial Psoriasis Drug
MT
Kanghong Pharmaceutical Gets Nod for Registration of Escitalopram Oxalate Tablets
MT
Kanghong Pharma's Aripiprazole Oral Solution Chosen for China's Centralized Drug Procurement
MT
Kanghong Pharma Gets FDA Nod to Trial Drug Against Fatty Liver Disease
MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Kanghong Pharmaceutical Gets US FDA's Clinical Trial Nod for Antidepressant
MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Executive Changes
CI
Kanghong Pharma Gets Nod to Trial Antidepressant
MT
Chengdu Hongji Biotechnology Co., Ltd. announced that it expects to receive CNY 159.736344 million in funding from Chengdu Kanghong Pharmaceutical Group Co., Ltd, Chengdu Kangji Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangyin Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangzhi Technology Consulting Partnership (Limited Partnership)
CI
Kanghong Pharma Gets Continued Protection for Traditional Chinese Medicine
MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on Share A for 2022, Payable on June 6, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002773 Stock
  4. News Chengdu Kanghong Pharmaceutical Group Co., Ltd